Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012, Int. J. Cancer, vol.136, pp.359-386, 2015. ,
, Cancer statistics, vol.62, pp.10-29, 2012.
EGFR-TKI resistant non-small cell lung cancer (NSCLC): new developments and implications for future treatment, Lung Cancer Amst. Neth, vol.77, pp.2-8, 2012. ,
Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers, Mol. Ther. J. Am. Soc. Gene Ther, vol.18, pp.528-535, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-00425468
Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma, J. Pathol, vol.225, pp.83-95, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-00598462
Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer, J. Biomed. Biotechnol, p.165214, 2011. ,
Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations, OncoTargets Ther, vol.9, pp.3711-3726, 2016. ,
Mechanisms of resistance to EGFR targeted therapies, Cancer Biol. Ther, vol.14, pp.304-314, 2013. ,
Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation, Mol. Ther. J. Am. Soc. Gene Ther, vol.18, pp.536-543, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-00425467
The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism, Int. J. Cancer, vol.134, pp.2560-2571, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02349444
,
Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma, OncoTargets Ther, vol.9, pp.6843-6855, 2016. ,
URL : https://hal.archives-ouvertes.fr/hal-02347748
Histone deacetylase inhibitors: molecular mechanisms of action, Oncogene, vol.26, pp.5541-5552, 2007. ,
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin, Proc. Natl. Acad. Sci. U. S. A, vol.99, pp.11700-11705, 2002. ,
Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells, Leukemia, vol.21, pp.2344-2353, 2007. ,
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma, Proc. Natl. Acad. Sci. U. S. A, vol.102, pp.8567-8572, 2005. ,
Histone Deacetylase Inhibitors (HDACi) Cause the Selective Depletion of Bromodomain Containing Proteins (BCPs), Mol. Cell. Proteomics, vol.14, pp.1350-1360, 2015. ,
Quantitative proteomic approach to understand metabolic adaptation in nonsmall cell lung cancer, J. Proteome Res, vol.13, pp.4695-4704, 2014. ,
Tubulin Beta-3 Chain as a New Candidate Protein Biomarker of Human Skin Aging: A Preliminary Study, Oxid. Med. Cell. Longev, p.5140360, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-02013107
General statistical modeling of data from protein relative expression isobaric tags, J. Proteome Res, vol.10, pp.2758-2766, 2011. ,
BioVenn -a web application for the comparison and visualization of biological lists using area-proportional Venn diagrams, BMC Genomics, vol.9, p.488, 2008. ,
ProteomeXchange provides globally coordinated proteomics data submission and dissemination, Nat. Biotechnol, vol.32, pp.223-226, 2014. ,
PANTHER in 2013: modeling the evolution of gene function, and other gene attributes, in the context of phylogenetic trees, Nucleic Acids Res, vol.41, pp.377-386, 2013. ,
, PLoS Comput. Biol, vol.11, p.1004085, 2015.
Sexual Dimorphism, Age, and Fat Mass Are Key Phenotypic Drivers of Proteomic Signatures, J. Proteome Res, vol.16, pp.4122-4133, 2017. ,
STAT1 as a key modulator of cell death, Cell. Signal, vol.19, pp.454-465, 2007. ,
, STATs get their move on, vol.2, p.27080, 2013.
The eEF1A Proteins: At the Crossroads of Oncogenesis, Apoptosis, and Viral Infections, Front. Oncol, vol.5, p.75, 2015. ,
A Comparison of nLC-ESI-MS/MS and nLC-MALDI-MS/MS for GeLC-Based Protein Identification and iTRAQ-Based Shotgun Quantitative Proteomics, J. Biomol. Tech. JBT, vol.18, pp.226-237, 2007. ,
A comparison of the accuracy of iTRAQ quantification by nLC-ESI MSMS and nLC-MALDI MSMS methods, J. Proteomics, vol.73, pp.1391-1403, 2010. ,
Analysis of the plasma proteome using iTRAQ and TMT-based Isobaric labeling, Mass Spectrom. Rev ,
P63 in health and cancer, Int. J. Dev. Biol, vol.59, pp.87-93, 2015. ,
A Quantitative Proteomics Analysis of Subcellular Proteome Localization and Changes Induced by DNA Damage, Mol. Cell. Proteomics MCP, vol.9, pp.457-470, 2010. ,
Dysregulation of microRNA biogenesis in cancer: the impact of mutant p53 on Drosha complex activity, J. Exp. Clin. Cancer Res, vol.35, p.45, 2016. ,
MicroRNA biogenesis pathways in cancer, Nat. Rev. Cancer, vol.15, pp.321-333, 2015. ,
MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis, J. Hum. Genet, vol.62, pp.57-65, 2017. ,
Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer, Int. J. Mol. Sci, vol.17, p.237, 2016. ,
Identification of Metabolic Signatures Associated with Erlotinib Resistance of Non-small Cell Lung Cancer Cells, Anticancer Res, vol.34, pp.2779-2787, 2014. ,
Glutathione metabolism in patients with non-small cell lung cancers, Cancer Res, vol.57, pp.152-155, 1997. ,
Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: A review, J. Clin. Oncol, vol.24, pp.1761-1769, 2006. ,
STAT-1: a novel regulator of apoptosis, Int. J. Exp. Pathol, vol.84, pp.239-244, 2003. ,
The good and the bad faces of STAT1 in solid tumours, Cytokine, vol.89, pp.12-20, 2017. ,
HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer, Cancer Res, vol.71, pp.4412-4422, 2011. ,
Upregulation of Stat1-HDAC4 confers resistance to etoposide through enhanced multidrug resistance 1 expression in human A549 lung cancer cells, Mol. Med. Rep, vol.11, pp.2315-2321, 2015. ,
Expression of protein elongation factor eEF1A2 predicts favorable outcome in breast cancer, Breast Cancer Res. Treat, vol.102, pp.31-41, 2007. ,
Identification of putative oncogenes in lung adenocarcinoma by a comprehensive functional genomic approach, Oncogene, vol.25, pp.2628-2635, 2006. ,
Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer, Nat. Genet, vol.31, pp.301-305, 2002. ,
The prognostic significance of elongation factor eEF1A2 in ovarian cancer, Gynecol. Oncol, vol.108, pp.561-568, 2008. ,
eEF1A2 protein expression correlates with lymph node metastasis and decreased survival in pancreatic ductal adenocarcinoma, Hepatogastroenterology, vol.60, pp.870-875, 2013. ,
Peptide Elongation Factor eEF1A-2/S1 Expression in Cultured Differentiated Myotubes and Its Protective Effect against Caspase-3-mediated Apoptosis, J. Biol. Chem, vol.277, pp.5418-5425, 2002. ,
Mouse translation elongation factor eEF1A-2 interacts with Prdx-I to protect cells against apoptotic death induced by oxidative stress, J. Cell. Biochem, vol.100, pp.267-278, 2007. ,
Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin, Sci. Rep, vol.6, p.35100, 2016. ,
, eEF1A2 activates Akt and stimulates Akt-dependent actin remodeling, invasion and migration, vol.26, pp.3027-3040, 2007.
Eef1a2 promotes cell growth, inhibits apoptosis and activates JAK/STAT and AKT signaling in mouse plasmacytomas, PloS One, vol.5, p.10755, 2010. ,